Analysts at HC Wainwright lifted their FY2024 earnings per share estimates for Larimar Therapeutics in a research report ...
1 Day LRMR 2.30% DJIA 0.89% Russell 2K 1.03% Health Care/Life Sciences 2.54% ...
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Larimar Therapeutics (LRMR – Research Report) yesterday and set a price target of $25.00. Joseph Schwartz has given his Buy rating ...
Equities research analysts at William Blair lifted their FY2024 EPS estimates for Larimar Therapeutics in a research note ...
Oct. 30, 2024 (GLOBE NEWSWIRE) -- October 30, 2024 – Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
Indeed, Larimar Therapeutics (NASDAQ:LRMR) stock is up 170% in the last year, providing strong gains for shareholders. Nonetheless, only a fool would ignore the risk that a loss making company ...
Oppenheimer sets Larimar Therapeutics' price target at $26, anticipating $1.2 billion in global revenues by 2030. The company aims for FDA marketing application submission in late 2025 ...
Shares of Larimar Therapeutics (NASDAQ:LRMR) gained on Wednesday after Oppenheimer launched the company with an Outperform recommendation, citing the potential of its lead asset, nomlabofusp ...
Today, Zacks Equity Research like Madrigal Pharmaceuticals MDGL, Corcept Therapeutics CORT, Catalyst Pharmaceuticals CPRX, Larimar Therapeutics LRMR and Theravance Biopharma TBPH. Industry: Small ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback